SHIELD THERAPEUTICS PLC (STX) — Q2 trading update

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SHIELD THERAPEUTICS PLC Q2 Trading Update. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. Company may not be in a position to answer every question it receives during the meeting itself. However, the company can review your questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to the management team of SHIELD THERAPEUTICS, Anders Santosh. Good afternoon. Good afternoon, Alex, and thank you for the introduction, and good afternoon, everybody. And if you happen to be on The U. S. Continent, good morning. So my name is Anders Lonsam. I'm the CEO of SHIELD THERAPEUTICS. And together with me this morning is Santos Schrambach, who is our CFO, and we together will walk you through the quarter two presentation and also the q and a following the actual presentation. Here's the disclaimer, and I'm not gonna give you much time to read it, but there it was, and we'll jump straight into it. So I will start by describing the company SHIELD THERAPEUTICS, our product, and the market. So iron deficiency is a is a very large market. And in The US alone, there's about fifteen million individuals every year that has iron deficiency with or without anemia. The typical treatment for iron deficiency is a ferrous salt as an oral treatment. And the challenge here is that about forty to sixty percent of patients cannot tolerate that that treatment. Acrefer, is the brand name in The US and Feracru typically the brand name outsid...